Retinal Vein Occlusion Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)
Description
The retinal vein occlusion market size was valued at USD 12.40 Billion in 2024 , driven by the rising incidence of geriatric population. The market is expected to grow at a CAGR of 13.03% during the forecast period of 2025-2034, with the values likely to reach USD 42.20 Billion by 2034 .
Retinal Vein Occlusion: Introduction
Retinal vein occlusion is a condition characterized by the blockage of small veins carrying blood away from the retina. It may induce sudden blurring or vision loss in one part or the entire eye. Retinal vein occlusion is caused by hardening of veins (atherosclerosis) and blood clot formation. The venous blockage can be broadly divided into two categories, namely, central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Treatment includes anti-vascular endothelial growth factor injections or focal laser procedures among others. The treatment may vary from patient to patient.
Retinal Vein Occlusion Market Analysis
With the increasing prevalence of sedentary lifestyle and obesity, the incidence of atherosclerosis, also known as hardening of the arteries, has increased. Atherosclerosis is one of the major causes of retinal vein occlusion along with other risk factors like diabetes, high blood pressure, macular edema, and glaucoma. The growing occurrence of these factors has fueled the retinal vein occlusion market demand.
Retinal vein occlusion management has been a key area of attention amongst the researchers. With the rising number of drug approvals for disease management, the market value is anticipated to grow in the forecast period. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on two phase III studies showcasing early and persistent vision improvements in patients with the condition.
The retinal vein occlusion market growth is driven by the advent of new diagnostic and management tools for facilitating better understanding of the pathophysiology of the disease. Multimodal imaging techniques such as optical coherence tomography (OCT), optical coherence tomography angiography, choroidal imaging and fundus fluorescein angiography are commonly used diagnostic methods.
Retinal Vein Occlusion Market Segmentation
“Retinal Vein Occlusion Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The retinal vein occlusion market share has been dominated by the United States in the historical period. The presence of key healthcare companies can be considered as a major factor fueling the market size. With a robust healthcare infrastructure, scientists can easily integrate numerous technical advancements into their research and develop effective treatment alternatives for the patients.
In Europe, the population is at a higher risk of retinal vein occlusion largely due to high geriatric population. Identifying the risk, the government has been proactive in providing the right awareness to the people. Moreover, the region has been witnessing mergers and acquisitions amongst MedTech companies to expand their product portfolio and cater to the market demand.
Retinal Vein Occlusion Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Retinal Vein Occlusion: Introduction
Retinal vein occlusion is a condition characterized by the blockage of small veins carrying blood away from the retina. It may induce sudden blurring or vision loss in one part or the entire eye. Retinal vein occlusion is caused by hardening of veins (atherosclerosis) and blood clot formation. The venous blockage can be broadly divided into two categories, namely, central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Treatment includes anti-vascular endothelial growth factor injections or focal laser procedures among others. The treatment may vary from patient to patient.
Retinal Vein Occlusion Market Analysis
With the increasing prevalence of sedentary lifestyle and obesity, the incidence of atherosclerosis, also known as hardening of the arteries, has increased. Atherosclerosis is one of the major causes of retinal vein occlusion along with other risk factors like diabetes, high blood pressure, macular edema, and glaucoma. The growing occurrence of these factors has fueled the retinal vein occlusion market demand.
Retinal vein occlusion management has been a key area of attention amongst the researchers. With the rising number of drug approvals for disease management, the market value is anticipated to grow in the forecast period. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on two phase III studies showcasing early and persistent vision improvements in patients with the condition.
The retinal vein occlusion market growth is driven by the advent of new diagnostic and management tools for facilitating better understanding of the pathophysiology of the disease. Multimodal imaging techniques such as optical coherence tomography (OCT), optical coherence tomography angiography, choroidal imaging and fundus fluorescein angiography are commonly used diagnostic methods.
Retinal Vein Occlusion Market Segmentation
“Retinal Vein Occlusion Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Branch Retinal Artery Occlusion
- Central Retinal Vein Occlusion
- Non-Ischemic
- Ischemic
- Optical Coherence Tomography (OCT)
- Fundoscopic Examination
- Fluorescein Angiography
- Others
- Antivascular Endothelial Growth Factor
- Corticosteroid Drugs
- Laser Retinal Photocoagulation
- Others
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The retinal vein occlusion market share has been dominated by the United States in the historical period. The presence of key healthcare companies can be considered as a major factor fueling the market size. With a robust healthcare infrastructure, scientists can easily integrate numerous technical advancements into their research and develop effective treatment alternatives for the patients.
In Europe, the population is at a higher risk of retinal vein occlusion largely due to high geriatric population. Identifying the risk, the government has been proactive in providing the right awareness to the people. Moreover, the region has been witnessing mergers and acquisitions amongst MedTech companies to expand their product portfolio and cater to the market demand.
Retinal Vein Occlusion Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Bayer AG
- IRIDEX Corporation
- Lumenis
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals
- Merck & Co.
- Carl Zeiss
- AbbVie Inc.
- CalciMedica Inc.
- Outlook Therapeutics, Inc.
- Kodiak Sciences Inc.
- Aerie Pharmaceuticals Inc.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Retinal Vein Occlusion Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Retinal Vein Occlusion Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3.2 France Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 5.4 Japan Retinal Vein Occlusion Epidemiology Forecast (2018-2034)
- 6 Retinal Vein Occlusion Market Overview – 7MM
- 6.1 Retinal Vein Occlusion Market Historical Value (2018-2024)
- 6.2 Retinal Vein Occlusion Market Forecast Value (2025-2034)
- 7 Retinal Vein Occlusion Market Landscape – 7MM
- 7.1 Retinal Vein Occlusion Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Retinal Vein Occlusion Product Landscape
- 7.2.1 Analysis by Products
- 7.2.2 Analysis by Type
- 7.2.3 Analysis by Route of Administration
- 8 Retinal Vein Occlusion Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Retinal Vein Occlusion Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Retinal Vein Occlusion Market Segmentation – 7MM
- 11.1 Retinal Vein Occlusion Market by Type
- 11.1.1 Market Overview
- 11.1.2 Branch Retinal Artery Occlusion
- 11.1.3 Central Retinal Vein Occlusion
- 11.2 Retinal Vein Occlusion Market by Condition
- 11.2.1 Market Overview
- 11.2.2 Non-Ischemic
- 11.2.3 Ischemic
- 11.3 Retinal Vein Occlusion Market by Diagnosis
- 11.3.1 Market Overview
- 11.3.2 Optical Coherence Tomography (OCT)
- 11.3.3 Fundoscopic Examination
- 11.3.4 Fluorescein Angiography
- 11.3.5 Others
- 11.4 Retinal Vein Occlusion Market by Treatment Type
- 11.4.1 Market Overview
- 11.4.2 Antivascular Endothelial Growth Factor
- 11.4.3 Corticosteroid Drugs
- 11.4.4 Laser Retinal Photocoagulation
- 11.4.5 Others
- 11.5 Retinal Vein Occlusion Market by End User
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Clinics
- 11.5.4 Ambulatory Surgical Centers
- 11.5.5 Homecare Settings
- 11.5.6 Others
- 11.6 Retinal Vein Occlusion Market by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 12 United States Retinal Vein Occlusion Market
- 12.1 Retinal Vein Occlusion Market Historical Value (2018-2024)
- 12.2 Retinal Vein Occlusion Market Forecast Value (2025-2034)
- 12.3 Retinal Vein Occlusion Market by Disease Type
- 12.4 Retinal Vein Occlusion Market by Treatment Type
- 13 EU-4 and United Kingdom Retinal Vein Occlusion Market
- 13.1 Retinal Vein Occlusion Market Historical Value (2018-2024)
- 13.2 Retinal Vein Occlusion Market Forecast Value (2025-2034)
- 13.3 Germany Retinal Vein Occlusion Market Overview
- 13.3.1 Retinal Vein Occlusion Market by Disease Type
- 13.3.2 Retinal Vein Occlusion Market by Treatment Type
- 13.4 France Retinal Vein Occlusion Market Overview
- 13.4.1 Retinal Vein Occlusion Market by Disease Type
- 13.4.2 Retinal Vein Occlusion Market by Treatment Type
- 13.5 Italy Retinal Vein Occlusion Market Overview
- 13.5.1 Retinal Vein Occlusion Market by Disease Type
- 13.5.2 Retinal Vein Occlusion Market by Treatment Type
- 13.6 Spain Retinal Vein Occlusion Market Overview
- 13.6.1 Retinal Vein Occlusion Market by Disease Type
- 13.6.2 Retinal Vein Occlusion Market by Treatment Type
- 13.7 United Kingdom Retinal Vein Occlusion Market Overview
- 13.7.1 Retinal Vein Occlusion Market by Disease Type
- 13.7.2 Retinal Vein Occlusion Market by Treatment Type
- 14 Japan Retinal Vein Occlusion Market
- 14.1 Retinal Vein Occlusion Market Historical Value (2018-2024)
- 14.2 Retinal Vein Occlusion Market Forecast Value (2025-2034)
- 14.3 Retinal Vein Occlusion Market by Disease Type
- 14.4 Retinal Vein Occlusion Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Allergan
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Bayer AG
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 IRIDEX Corporation
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Lumenis
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Novartis AG
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 F. Hoffmann-La Roche Ltd
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Regeneron Pharmaceuticals
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Merck & Co.
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 Carl Zeiss
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 AbbVie Inc.
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 CalciMedica Inc.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Outlook Therapeutics, Inc.
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Kodiak Sciences Inc.
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Aerie Pharmaceuticals Inc.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 21 Retinal Vein Occlusion Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
